Pilot: MRI Differences Associated with Dutasteride and Finasteride Treatments in Patients with Low Risk Prostate Cancer
Olga Starobinets 1,2 , John Kornak 3 , John Kurhanewicz 1,2 , and Susan M Noworolski 1,2
Radiology and Biomedical Imaging, UCSF, San
Francisco, CA, United States,
Group in Bioengineering, UC Berkeley, Berkeley, CA,
and Biostatistics, UCSF, San Francisco, CA, United
Majority of imaging parameters obtained during a
prostate mpMRI scan demonstrate a better separation
between low-grade cancerous and benign regions for
prostate tissues exposed to anti-androgen therapy.
Pretreatment with dutasteride or finasteride may
facilitate a better detection of low-grade prostate
This abstract and the presentation materials are available to members only;
a login is required.